Good comments, thanks. And on further review,
I can't find too many reasons to add CTIC to
the Biotech Valuation spreadsheet, not just yet.
I just spend the last hour slogging through the
last few press releases, the quarterly and annual
reports--and while it is certainly cheap enough to
make the first cut to get back on my watch list
marketcap=book) maybe it can stay off DAK's list
for now--in fact, I wonder if the spreadsheet has
already become a bit unwieldy without me adding my
ultra cheap stuff--there are nearly 40 biotechs in
the spreadsheet now, yikes!
___*OT* CTIC stuff follows_______
That said, maybe it was not too big a surprise that
LSF did not improve survival for ARDS, I see in an
earlier PR from cti, that 40% of these people die of
their 'catastropic medical condition', whether it be
pneumonia, shock, sepsis, trauma. Well, let's see how
LSF phase III goes for lung infection (chemo Acute
Myeloid Leukemia) and LSF phase III--BMT. CTI also
has efficacy trial of Apra (CT-2584) in refractory
prostate cancer. Also Apra for soft tissue sarcomas,
and later this year cti expects to extend the
application of Apra to studies involving combination
with chemotherapy for lung cancer.
So, lots going on, lots of cash will burn up next two
years, in fact, they may only have a year of cash left
if they jump on everything at once.
Clinical trials with PG-TXL are anticipated to begin
late in the second half of the year, ahead of original
projections. Since obtaining an exclusive option for an
exclusive worldwide license to SC-7 in December 1998, cti
expects to begin preclinical studies shortly in preparation
for an IND late next year.
burn baby burn, well, that's the way it works, I knew what
I was getting myself into, besides, like I said, just a toe
in the water, wasn't like I loaded up Friday.
Very easy for me to throw darts at microcap biotechs which
happen to be trading at book value, but also a good idea
to narrow these lists through the SI-biotech-guru filter:
Has Rick, or Peter or Miljenko or any of the other fellas
here on SI ever posted to the CTIC thread with enthusiastic
comments, dunno, maybe I will go slog through those some
time.
Anyway, long post, sorry, but bottom line is that, for now,
I withdraw CTIC for inclusion on Dave's list, somebody else
will have to nominate it and back it up with some science--
and that is something I cannot do. Besides, I've got several
things that don't appear on the current spreadsheet, it
would not be the first time I bought stock of something that
has not been through the extra filters;-) Might be fun to
watch the performance of my unfiltered-book-value microcap
bitoechs, versus Dave's slightly better-filtered brew. |
